Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)
Not Applicable
- Conditions
- Pulmonary Hypertension
- Registration Number
- NCT04088279
- Lead Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Brief Summary
A prospective study of the use of two novel MRI techniques (oxygen-enhanced and fourier decomposition MRI) in the initial diagnosis and follow-up of patients with Pulmonary Hypertension. The investigators believe these techniques may present a novel set of imaging biomarkers that may be used for risk stratification, prediction of treatment response and longitudinal disease monitoring. The reserach MRI is in addition to standard of care and will not affect treatment decisions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Confirmed diagnosis of Pulmonary Hypertension.
- Age 18 and over.
Exclusion Criteria
- Standard contra-indications to MRI (as per NHS MRI safety questionnaire).
- Not medically fit for transfer to MRI.
- Patient judged inappropriate for involvement in study by clinical team e.g. secondary to emotional burden of recent diagnosis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Fractions (% area of lung imaged) Baseline and 3-6 months Delta pO2 max (mmHg) Baseline and 3-6 months Wash in and wash out time constants (min) Baseline and 3-6months Signal Intensity Change (%) Baseline and 3-6months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Royal Brompton Hospital
🇬🇧London, United Kingdom